San Francisco – July 20, 2021 – Cooley advised Lyell Immunopharma, a T cell reprogramming company dedicated to the mastery of T cells to cure patients with solid tumors, on its $425 million initial public offering of 25,000,000 shares of its common stock. Partners Dave Peinsipp, Charlie Kim, Chad Mills and Lauren Creel led the Cooley team advising Lyell on its public debut, which marks the third largest biotech IPO in history. 

Goldman Sachs & Co. LLC, BofA Securities, J.P. Morgan and Morgan Stanley acted as joint book-running managers for the offering.

Lyell focuses on addressing what it believes are the primary barriers that limit consistent, reliable and curative responses with adoptive T cell therapy: T cell exhaustion and loss of durable stemness, which includes proliferative capacity, ability to self-renew and ability to differentiate and eliminate solid tumors. The company is applying its proprietary ex vivo genetic and epigenetic reprogramming technology platforms, Gen-R and Epi-R, to address these barriers in order to develop new medicines with improved, durable and potentially curative clinical outcomes. Lyell is based in South San Francisco, Seattle and Bothell, Washington. Its securities now trade on the Nasdaq Global Select Market under the symbol “LYEL.”

About Cooley LLP

Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation, where innovation meets the law. 

Cooley has 1,300 lawyers across 17 offices in the United States, Asia and Europe.